Vitamin D and COVID‐19 in an immunocompromised patient with multiple comorbidities

Vitamin D study #87 of 131 Meta Analysis

3/5 Analysis of outcomes based on serum levels

Kralj et al., Critical Case Reports, doi:10.1002/ccr3.4010 (Peer Reviewed)
Vitamin D and COVID‐19 in an immunocompromised patient with multiple comorbidities—A Case Report

Source PDF Share Tweet

Case report of a high-risk immunocompromised patient with multiple comorbidities that had a mild case of COVID-19. The patient had UVB phototherapy three months earlier and had normal vitamin D levels (92.2 nmol/L, normal range 50-125).

Kralj et al., 3/5/2021, peer-reviewed, 2 authors.

All 131 studies Meta Analysis

Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.

Submit